By Frank Prenesti
Date: Tuesday 09 May 2023
LONDON (ShareCast) - (Sharecast News) - AstraZeneca's Farxiga drug has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults, the company said on Tuesday.
The approval by the Food and Drug Administration was based on positive results from the DELIVER Phase III trial.1 Farxiga was previously approved in the US for adults with heart failure with reduced ejection fraction.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 11,042.00p |
Change Today | -164.00p |
% Change | -1.46 % |
52 Week High | 13,276.00 |
52 Week Low | 9,501.00 |
Volume | 2,329,887 |
Shares Issued | 1,550.29m |
Market Cap | £171,184m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 9 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 30 |
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 08-Aug-24 | 22-Feb-24 |
Paid | 09-Sep-24 | 25-Mar-24 |
Amount | 100.00¢ | 197.00¢ |
Time | Volume / Share Price |
16:09 | 179,211 @ 11,160.00p |
16:51 | 488 @ 11,042.00p |
16:51 | 142 @ 11,042.00p |
16:35 | 3,725 @ 11,042.00p |
16:35 | 75 @ 11,042.00p |
You are here: research